Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting.

First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital, the South Australian Health and Medical Research Institute, and the University of Adelaide in Australia, reported higher efficacy in terms of major molecular responses and lower toxicity with asciminib. After his talk in Chicago, he met up with Oncology Times reporter, Peter Goodwin.